Claire Dawson
Dana-Farber Cancer Institute is a cancer treatment and research facility in Boston, Massachusetts. It is nationally ranked in 1 adult and 1 pediatric specialty and rated high performing in 5 adult procedures and conditions. Dana-Farber has been ranked the sixth-best cancer hospital in the US and fifth by U.S. News & World Report. The institute has led the way in cancer breakthroughs for over 75 years and is known for its revolutionary discoveries that are changing cancer treatment. Dana-Farber is also a principal teaching affiliate of Harvard Medical School and a federally designated Center for AIDS Research.
Explore related products
What You'll Learn
Dana-Farber Cancer Institute's ranking
Dana-Farber Cancer Institute is a dedicated cancer treatment and research facility based in Boston, Massachusetts. The institute is a principal teaching affiliate of Harvard Medical School and is also a federally designated Center for AIDS Research. Dana-Farber has a long history of breakthroughs in cancer treatment and research, including the first temporary remissions of acute lymphocytic leukemia, a common childhood cancer, in 1947.
As of 2024, Dana-Farber is ranked the sixth-best cancer hospital in the US. It is rated highly in several areas, including cancer, colon cancer surgery, gynecological cancer surgery, leukemia, lymphoma, myeloma, lung cancer surgery, and prostate cancer surgery. Expertscape ranks its programs in aplastic anemia and multiple myeloma as the best in the world. Dana-Farber has also been ranked the fifth-best cancer hospital in the US by U.S. News & World Report, which has recognized the institute for its clinical innovations in emerging cellular therapies, immuno-oncology, and adaptive radiation therapy.
Dana-Farber has a strong record of producing groundbreaking research. Its researchers have contributed to the development of an immune checkpoint inhibitor drug for patients with locally advanced head and neck cancer, which was approved by the FDA in 2025. The institute has also launched a specialized cancer navigation program for firefighters and a novel cancer screening test for veterans.
In recent years, Dana-Farber has expanded its operations. In 2023, the institute announced a partnership with Beth Israel Deaconess Medical Center to build a new standalone inpatient hospital focused on treating adult cancer patients. This $1.7 billion, 300-bed facility is expected to open in 2028. However, this expansion has faced some skepticism from healthcare experts, who argue that it may increase costs for patients and negatively impact smaller hospitals.
Overall, Dana-Farber Cancer Institute is recognized as a leading cancer treatment and research facility, consistently ranked among the top cancer hospitals in the US for its innovative treatments and contributions to cancer research.
US Hospital Computers: Down and Out?
You may want to see also
Explore related products
The institute's history and mission
Dana-Farber Cancer Institute, located in Boston, Massachusetts, is a world-leading cancer treatment and research facility. The institute was founded in 1948 by Dr. Sidney Farber, a pioneer in cancer research and care. Dr. Farber's vision was to create a centre dedicated equally to groundbreaking cancer research and compassionate, patient-centred care.
In its initial years, the institute focused on treating children with cancer, supported by the Jimmy Fund, which was established in Boston in 1948. The Jimmy Fund has been instrumental in raising funds for Dana-Farber through various community-led events, including walks, races, auctions, and golf tournaments. With the support of the Boston Red Sox owners, Tom and Jean Yawkey, the Jimmy Fund became the team's official charity, further strengthening its fundraising capabilities.
Over time, Dana-Farber expanded its programmes to include patients of all ages. In 1969, the institute began treating patients of all ages, and in 1974, it was renamed the Sidney Farber Cancer Center in honour of its founder. The institute's name was again changed in 1983 to acknowledge the long-term support of the Charles A. Dana Foundation.
Today, Dana-Farber Cancer Institute remains committed to Dr. Sidney Farber's original vision. The institute employs over 5,000 staff, faculty, and clinicians, serving more than 640,000 outpatients annually and conducting over 1,100 open clinical trials. Dana-Farber is recognised for its dual commitment to cutting-edge research and excellent patient care, which has positioned it at the forefront of cancer treatment and breakthroughs.
The institute's mission is solely focused on defeating cancer. Patients at Dana-Farber are treated by specialists in their particular type of cancer, ensuring personalised and multidisciplinary care. Dana-Farber has been recognised as one of the top cancer centres in the nation by U.S. News & World Report. Through its innovative research and dedication to patient care, Dana-Farber continues to make significant contributions to the fight against cancer.
Effective Ways to Remove Hospital Tape Residue
You may want to see also
Explore related products
Areas of specialty
Dana-Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts. Dana-Farber has been at the forefront of cancer breakthroughs for more than 75 years and is committed to Dr. Sidney Farber's vision of a cancer center dedicated to both research and patient-centered care.
Dana-Farber has a long history of breakthroughs in cancer care and research. Some notable examples include:
- Leukemia Treatment: In 1947, Sidney Farber led a team that achieved the first temporary remissions of acute lymphocytic leukemia, the most common cancer in children, using aminopterin.
- Wilms' Tumor Treatment: In 1954, Farber and his colleagues boosted cure rates for Wilms' tumor, a common childhood cancer, from 40% to 85%.
- Myelogenous Leukemia Treatment: In 1976, researchers at the institute developed a new treatment for acute myelogenous leukemia.
- Breast Cancer Treatment: Dana-Farber has been involved in advancements in breast cancer treatment. For example, T-DXd Plus Pertuzumab has been found to outperform the standard of care for first-line treatment of advanced HER2-positive breast cancer.
- Colon Cancer Treatment: Research at Dana-Farber has shown that adding an immune checkpoint inhibitor to the standard chemotherapy regimen improves outcomes in Stage 3 colon cancer.
- Lung Cancer Treatment: The institute has contributed to the development of a promising chemoimmunotherapy strategy for aggressive Stage III non-small cell lung cancer.
- Head and Neck Cancer Treatment: Dana-Farber's research has led to the FDA approval of an immune checkpoint inhibitor drug for patients with resectable locally advanced head and neck cancer.
- Cancer Screening: The institute has introduced a novel cancer screening test for veterans.
- Cancer Navigation Programs: Dana-Farber has launched specialized cancer navigation programs for specific groups, such as firefighters.
- Blood Disorders: Dana-Farber/Boston Children's Cancer and Blood Disorders Center specializes in treating and caring for children with blood disorders and all types of childhood cancers.
Dana-Farber has 13 specialized disease treatment centers dedicated to providing individualized care for specific types of cancer. The institute is also a principal teaching affiliate of Harvard Medical School and a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), a comprehensive cancer research consortium. Additionally, it is a federally designated Center for AIDS Research.
Expertscape ranks Dana-Farber's programs in aplastic anemia and multiple myeloma as the best in the world. As of 2024, it is ranked as the sixth-best cancer hospital in the US, and U.S. News & World Report ranks it as one of the top five cancer centers in the nation.
Surgery Centers: Are They as Safe as Hospitals?
You may want to see also
Explore related products
$56.63 $74.99
The institute's partnerships
Dana-Farber Cancer Institute is a comprehensive cancer treatment and research center in Boston, Massachusetts. The institute has a long history of breakthrough discoveries in cancer care and research. It is also known for its compassionate patient care. Dana-Farber has been ranked the #6 cancer hospital in the US as of 2024.
Dana-Farber has several partnerships with other institutions and organizations to further its mission of providing expert, compassionate cancer care and advancing cancer research. Here are some of its key partnerships:
- Brigham and Women's Hospital: Dana-Farber has a long-time affiliation with Brigham and Women's Hospital, recognized as one of the top cancer care facilities by U.S. News & World Report. Together, they established the Dana-Farber Brigham Cancer Center, which provides personalized, multidisciplinary cancer care for adults.
- Harvard Medical School: Dana-Farber is a principal teaching affiliate of Harvard Medical School and is a founding member of the Dana-Farber/Harvard Cancer Center (DF/HCC), one of the federally designated Comprehensive Cancer Centers. This partnership allows Dana-Farber to provide advanced training in cancer treatment and research, as well as collaborate on community-based programs in cancer prevention, detection, and control.
- Boston Children's Hospital: Dana-Farber has a more than 70-year-old partnership with Boston Children's Hospital, delivering comprehensive care to children with all types of childhood cancers.
- St. Elizabeth's Medical Center: Dana-Farber collaborates with St. Elizabeth's Medical Center to provide outpatient services for adults with cancer through the Dana-Farber/St. Elizabeth's Cancer Center (DF/SEMC).
- Massachusetts General Hospital: Dana-Farber works with Massachusetts General Hospital and other Boston institutions on joint programs and initiatives.
- National Cancer Institute (NCI): As a Comprehensive Cancer Center designated by the NCI, Dana-Farber receives support and recognition from this important institution.
- National Institute of Allergy and Infectious Diseases (NIAID): Dana-Farber is supported by the NIAID, as well as private foundations and individual contributions.
- The Jimmy Fund: The Jimmy Fund is the principal charity of the Institute, named after one of its child patients. The Boston Red Sox adopted the Jimmy Fund as its official charity in 1953 and continues to be a prominent sponsor.
- PMC Unpaved: PMC Unpaved is a fundraising initiative that organizes a gravel bike ride to raise funds for cancer research and treatment at Dana-Farber.
- Beth Israel Deaconess Medical Center: Dana-Farber recently announced a partnership with Beth Israel Deaconess Medical Center to build a new standalone inpatient hospital focused on treating adult cancer patients.
Saint Jude's Hospital: Where is it Located?
You may want to see also
Explore related products
Controversies and criticism
In 2024, the Dana-Farber Cancer Institute was embroiled in a scandal that made national headlines. British molecular biologist Sholto David accused Dana-Farber researchers of manipulating images and falsifying data in several studies. The accusations reached the highest levels of the organisation, implicating President and CEO Dr Laurie Glimcher, Executive Vice President and COO William Hahn, and other well-known researchers.
Following these accusations, Dana-Farber launched an internal investigation and ultimately retracted six papers and corrected 31 others, with one paper still under examination. While the institute emphasised its commitment to integrity and accountability, marketing and risk management experts warned that the scandal could hurt its reputation, particularly as it coincided with a $2 billion fundraising campaign.
Some experts defended Dana-Farber, noting that correcting the scientific record is not unusual and that most publications are done in good faith. Barrett Rollins, the institute's research integrity officer, stated that Dana-Farber had already addressed some issues before they were cited in David's blog and that the errors may have been unintentional.
The scandal also led to discussions about the vetting systems used by scientific journals, with some arguing that the majority of publications are legitimate and should not be overshadowed by rare instances of misconduct.
The fallout from this incident highlighted the potential impact on Dana-Farber's longstanding reputation and partnerships, including its nearly 30-year relationship with Brigham and Women's Hospital. The institute's response to the crisis and its transparency in communicating the findings of its investigation were deemed crucial in mitigating potential long-term damage.
Katz Women's Hospital: North Shore's Leading Healthcare Provider
You may want to see also
Frequently asked questions
Dana-Farber is a good cancer hospital. It is ranked the 6th best cancer hospital in the US and is recognised as one of the top five cancer centres in the country. The hospital has a long history of breakthroughs in cancer care and research, and its revolutionary discoveries are changing cancer treatment globally.
Dana-Farber is focused exclusively on cancer patients. Patients at Dana-Farber are treated by specialists in their particular type of cancer. The hospital is also a principal teaching affiliate of Harvard Medical School and is a founding member of the Dana–Farber/Harvard Cancer Center, a research consortium that is one of the 39 federally designated comprehensive cancer centres.
Dana-Farber treats a wide range of cancers, including breast cancer, colon cancer, head and neck cancer, non-small cell lung cancer, leukaemia, lymphoma, myeloma, and prostate cancer.
To make an appointment at Dana-Farber, you can call the hospital directly or submit an appointment request form online. Schedulers from Brigham and Women's Hospital will then contact you to set up an appointment with a specialist.
